Mixed amphetamine salts: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) No edit summary |
MDElliottMD (talk | contribs) Migrated 7 indication tag(s) to global ref= |
||
| Line 18: | Line 18: | ||
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | | intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | ||
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a medicine in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular medicines in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world. | Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a medicine in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular medicines in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world. | ||
| indications = <indication | | indications = <indication ref="adhd" author="MDElliottMD"/> | ||
<indication | <indication ref="narcolepsy" author="MDElliottMD"/> | ||
<indication | <indication ref="trd-augment" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</indication> | </indication> | ||
<indication | <indication ref="shift-work" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</indication> | </indication> | ||
<indication | <indication ref="chronic-illness-cog" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</indication> | </indication> | ||
<indication | <indication ref="impulsivity" author="MDElliottMD"/> | ||
<indication | <indication ref="distractibility" author="MDElliottMD"> | ||
Impoved sustained attention by decreasing distractibility | Impoved sustained attention by decreasing distractibility | ||
</indication> | </indication> | ||